Stock Plans (Tables)
|
3 Months Ended |
Mar. 31, 2024 |
|---|
| Schedule of Stock-based Compensation Expense |
The Company’s stock-based compensation expense by type of award and by operating expense grouping are presented below:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31, |
|
|
|
2024 |
|
|
2023 |
|
Stock-based compensation expense by type of award: |
|
|
|
|
|
|
Restricted stock units |
|
$ |
830 |
|
|
$ |
2,168 |
|
Performance-based stock units |
|
|
— |
|
|
|
328 |
|
Stock options |
|
|
622 |
|
|
|
971 |
|
Employee stock purchase plan |
|
|
156 |
|
|
|
450 |
|
Total stock-based compensation expense |
|
$ |
1,608 |
|
|
$ |
3,917 |
|
|
|
|
|
|
|
|
Stock-based compensation expense by operating expense grouping: |
|
|
|
|
|
|
Cost of revenue |
|
$ |
(1 |
) |
|
$ |
20 |
|
Sales and marketing |
|
|
176 |
|
|
|
176 |
|
Research and development |
|
|
532 |
|
|
|
1,542 |
|
General and administrative |
|
|
901 |
|
|
|
2,179 |
|
Total stock-based compensation expense |
|
$ |
1,608 |
|
|
$ |
3,917 |
|
|
| Schedule of Performance Stock Unit Activity |
The Company’s performance stock unit activity for the three months ended March 31, 2024 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
Average Grant |
|
|
|
Shares |
|
|
Date Fair Value |
|
Unvested at December 31, 2023 |
|
|
229,633 |
|
|
$ |
5.86 |
|
Forfeited |
|
|
(59,231 |
) |
|
$ |
5.94 |
|
Unvested at March 31, 2024 |
|
|
170,402 |
|
|
$ |
5.86 |
|
|
| Schedule of Restricted Stock Unit Activity |
The Company’s restricted stock unit activity for the three months ended March 31, 2024 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted |
|
|
|
|
|
|
Average Grant |
|
|
|
Shares |
|
|
Date Fair Value |
|
Unvested at December 31, 2023 |
|
|
1,949,514 |
|
|
$ |
5.40 |
|
Granted |
|
|
3,000 |
|
|
$ |
3.88 |
|
Forfeited |
|
|
(186,560 |
) |
|
$ |
6.73 |
|
Vested |
|
|
(153,085 |
) |
|
$ |
7.30 |
|
Unvested at March 31, 2024 |
|
|
1,612,869 |
|
|
$ |
5.01 |
|
|
| Schedule of Stock Option Activity |
The activity during the three months ended March 31, 2024 related to all other stock options was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-Average |
|
|
|
|
|
|
|
|
|
Remaining |
|
Aggregate |
|
|
|
|
|
|
Exercise |
|
|
Contractual |
|
Intrinsic |
|
|
|
Options |
|
|
Price |
|
|
Term |
|
Value |
|
Outstanding at December 31, 2023 |
|
|
5,506,374 |
|
|
$ |
13.81 |
|
|
|
|
|
|
Exercised |
|
|
(17,521 |
) |
|
$ |
2.85 |
|
|
|
|
|
|
Forfeited |
|
|
(153,353 |
) |
|
$ |
8.86 |
|
|
|
|
|
|
Expired |
|
|
(78,939 |
) |
|
$ |
10.28 |
|
|
|
|
|
|
Outstanding at March 31, 2024 |
|
|
5,256,561 |
|
|
$ |
14.04 |
|
|
4.1 years |
|
$ |
1,120 |
|
Exercisable at March 31, 2024 |
|
|
4,799,140 |
|
|
$ |
14.10 |
|
|
3.7 years |
|
$ |
1,041 |
|
|
| Employee Stock Purchase Plan [Member] |
|
| Summary of Fair Value Assumptions of Stock Purchase Plan |
The assumptions used in calculating the fair values of purchase rights granted under the ESPP during the three months ended March 31, 2024 and 2023 are set forth in the table below:
|
|
|
|
|
|
|
Three Months Ended
March 31, |
|
|
2024 |
|
2023 |
Expected term (in years) |
|
0.5 - 2.0 |
|
0.5 - 2.0 |
Expected volatility |
|
105% - 115% |
|
71% - 101% |
Risk-free interest rate |
|
4.7% - 5.2% |
|
0.1% - 4.8% |
|
| Stock Options [Member] |
|
| Schedule of Fair Value Assumptions |
The assumptions used to compute the grant date fair values of the stock options granted during the three months ended March 31, 2024 and 2023 are set forth in the table below:
|
|
|
|
|
|
|
Three Months Ended
March 31, |
|
|
2024 |
|
2023 |
Expected term (in years) |
|
N/A |
|
6.8 |
Expected volatility |
|
N/A |
|
91% |
Risk-free interest rate |
|
N/A |
|
3.6% |
|
| Performance-based Stock Options [Member] |
|
| Schedule of Stock Option Activity |
The activity during the three months ended March 31, 2024 related to stock options that are subject to performance-based vesting conditions tied to the achievement of stock price goals by the Company was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-Average |
|
|
|
|
|
|
|
|
|
Remaining |
|
Aggregate |
|
|
|
|
|
|
Exercise |
|
|
Contractual |
|
Intrinsic |
|
|
|
Options |
|
|
Price |
|
|
Term |
|
Value |
|
Unvested at December 31, 2023 |
|
|
3,671,310 |
|
|
$ |
11.29 |
|
|
|
|
|
|
Expired |
|
|
(21,840 |
) |
|
$ |
5.78 |
|
|
|
|
|
|
Outstanding at March 31, 2024 |
|
|
3,649,470 |
|
|
$ |
11.32 |
|
|
6.2 years |
|
$ |
1 |
|
Exercisable at March 31, 2024 |
|
|
3,649,470 |
|
|
$ |
11.32 |
|
|
6.2 years |
|
$ |
1 |
|
|